Welcome to Novo Nordisk in the United States

Declarations


Declarations

Novo Nordisk’s disclosure regarding the California Transparency Supply Chain Act of 2010

Novo Nordisk complies with the California Transparency in Supply Chain Act of 2010 (SB 657) which became effective on January 1, 2012. The law requires manufacturers and retailers to disclose their efforts to eradicate slavery and human trafficking from the supply chain. The following information describes Novo Nordisk’s efforts to achieve these important goals.

Novo Nordisk’s social and environmental responsibility extends throughout the value chain to include the company’s suppliers. We have implemented global standards for responsible sourcing to ensure the company and our suppliers document performance in terms of compliance with laws and regulations, environment, health and safety, labor practices including those of children, forced, bonded, indentured or involuntary prison labor, business ethics, animal welfare and sub suppliers. Please see our Responsible Sourcing Standards for Business Partners for additional detail in this area.

Novo Nordisk supports the United Nations Universal Declaration of Human Rights. Besides being an active subscriber to the UN Global Compact since 2002, the company has joined the Global Compact LEAD, a platform for a select group of UN Global Compact companies to drive leadership to the next generation of sustainability performance.

We support collaborative industry and multi-stakeholder initiatives to improve sustainable performance in the supply chain and responsible sourcing to improve labor working conditions. Our membership and participation in two important initiatives documents this commitment.

  • The Pharmaceutical Supply Chain Initiative is a group of major pharmaceutical companies who share a vision for better social, economic and environmental conditions for all involved in the pharmaceutical supply chain. This includes working towards improved conditions for workers, economic development and a cleaner environment for local communities.
  • The Danish Ethical Trading Initiative is the first Danish multi-stakeholder initiative to bring together trade unions, business associations, non-governmental organizations and companies to promote ethical trade and responsible supply chain management.

For more information about Novo Nordisk’s responsible sourcing approach including expectations of suppliers, a risk based approach of supplier verification, our responsible sourcing contract clause, auditing processes, supplier monitoring systems, and internal knowledge building please refer to our website and online annual report.

2014 Declaration of Compliance

For the annual period beginning January 1, 2013 and concluding December 31, 2013, Novo Nordisk set an annual aggregate limit on promotional expenditures provided to California healthcare professionals of $2,000 per covered healthcare professional. Based upon our current internal monitoring process, to the best of our knowledge and belief, and based on a good faith understanding of California Health & Safety Code §§ 119400-402, Novo Nordisk is in compliance in all material respects with the requirements described in California SB1765. Novo Nordisk will continually evaluate and update its Compliance Program as necessary and appropriate, given the changing environment and needs.

Any third party who has any concerns regarding the Company’s or any individual employee’s compliance with this Compliance Program is encouraged to call the Compliance Hotline at 1-888-536-1504.

A copy of this document may be obtained by calling 1-800-727-6500.

California Public Resources Code Sections 47115-47116:
Required Reporting by Pharmaceutical Manufacturer
Novo Nordisk Inc.

Novo Nordisk is a Danish based health care company and a world leader in diabetes care. Novo Nordisk’s North American headquarters are located at 100 College Road West, Princeton, New Jersey, 08540. Novo Nordisk has approximately 1166 employees in Princeton and 2174 employees in the field.

Pursuant to the California Public Resources Code Sections 47115-47116, listed below are currently marketed Novo Nordisk products that utilize sharps and the steps we take to ensure safe disposal.

Our diabetes portfolio includes the following injectable products:

  • Levemir® (insulin detemir [rDNA origin] injection)
  • NovoLog® (insulin aspart [rDNA origin] injection)
  • NovoLog® (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) Mix 70/30
  • Novolin® R (regular, human insulin injection [recombinant DNA origin] USP)
  • Novolin® N (NPH, Human Insulin Isophane Suspension Injection [recombinant DNA origin])
  • Victoza® (liraglutide [rDNA origin] injection)

Our Biopharmaceutical portfolio includes the following injectable products:

  • Norditropin® (somatropin [rDNA origin] injection)
  • NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable)

Our delivery systems include (both diabetes and biopharmaceutical):

  • FlexPen®
  • GlucaGen® HypoKit®
  • NovoFine® Needles
  • NovoFine® Autocover® Needles
  • NovoPen® 3
  • NovoPen® Junior
  • PenMate®
  • FlexPro®

Conflict Minerals Disclosure

Please click here to view Novo Nordisk’s disclosure regarding Conflict Minerals.

Employee Disposal

All of our field personnel are trained on the safe disposal of products. Samples and/or devices that are expired or compromised are packaged and returned to Capital Returns Inc., located at 6101 North 64th Street, Milwaukee, Wisconsin, for destruction. Capital Returns is a certified medical waster disposal company that processes and destroys returned products.

Patient Returns

In the event a patient has an issue with a Novo Nordisk product, an 800 number is listed on our packaging for consumers to call for information and to report complaints. Patients who wish to return products due to defect can call that number and a customer service representative will register the complaint and then send a special shipping container to the patient. The patient subsequently returns the product to the Novo Nordisk manufacturing site in Clayton, North Carolina for investigation and subsequent destruction. Product that may require more detailed investigation is subsequently shipped to Denmark for additional analysis. A replacement product is then sent out to the patient. As per regulations, we inform the US Food and Drug Administration (FDA) of all patient reactions and certain product complaints, at minimum on an annual basis.

Patient Use and Education

Novo Nordisk provides hard copy and electronic educational materials for all of our sharp-using and sharp containing products. These materials include product inserts and product web pages (www.novonordisk-us.com). Proper use and disposal of sharps is covered in these materials.

We do not provide sharps containers for diabetes products nor do we supply funding to patients and/or other collection groups for the destruction of such materials. However, we do include a sharps container in the pediatric starter kit for Norditropin®. All of our material and literature are reviewed and approved internally, and sent to the FDA for review as per regulations. The material we provide on the use and disposal of sharps is comprehensive and simple to understand.

Diabetes

For patients using Novo Nordisk diabetes products we recommend the use of our NovoFine® and/or Autocover needles for all of our medication delivery systems. The patient literature supplied with these delivery systems illustrates the proper way to use and dispose of needles – that is to remove the cap and dispose of according to local and/or municipal regulations.

Biopharmaceuticals

NovoSeven® RT is a product that is primarily administered in a clinical setting. Patients treated with NovoSeven® RT under the FDA approved indication receive this product for:

  1. Bleeding episodes in hemophiliacs with inhibitors to FVIII or FIX; and
  2. In patients with acquired hemophilia and to prevent bleeds during surgical interventions or invasive procedures.

Materials related to administration of the product are disposed of according to the appropriate policies and procedures of the dosing institution for the destruction of biological waste.

Norditropin®, a product treating growth hormone deficiency, also uses a pen delivery system, in conjunction with our NovoFine® or Autocover needles. Educational materials and literature for this product illustrate the proper way to use and dispose of needles. For new pediatric patients using Norditropin®, our starter kit does include a sharps container for safe disposal of needles but no additional support is provided for disposition of needles, after receipt of the initial sharps container.

Important Safety Information

VICTOZA®Back to Top

Indications and Usage:


Victoza® (liraglutide [rDNA origin] injection) is an injectable prescription medicine that may improve blood sugar (glucose) in adults with type 2 diabetes when used along with diet and exercise.

Victoza® is not recommended as the first medication to treat diabetes. Victoza® is not a substitute for insulin and has not been studied in combination with prandial (meal-time) insulin. Victoza® is not for people with type 1 diabetes or people with diabetic ketoacidosis. It is not known if Victoza® is safe and effective in children. Victoza® is not recommended for use in children.

Important Safety Information:


In animal studies, Victoza® caused thyroid tumors—including thyroid cancer—in some rats and mice. It is not known whether Victoza® causes thyroid tumors or a type of thyroid cancer called medullary thyroid cancer (MTC) in people, which may be fatal if not detected and treated early. Do not use Victoza® if you or any of your family members have a history of MTC or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). While taking Victoza®, tell your doctor if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.


Do not use Victoza® if you are allergic to liraglutide or any of the ingredients in Victoza®. Serious allergic reactions can happen with Victoza®. If symptoms of serious allergic reactions occur, stop taking Victoza® and seek medical attention. Inflammation of the pancreas (pancreatitis) may be severe and lead to death. Before taking Victoza®, tell your doctor if you have had pancreatitis, gallstones, a history of alcoholism, or high blood triglyceride levels since these medical conditions make you more likely to get pancreatitis.

Stop taking Victoza® and call your doctor right away if you have pain in your stomach area that is severe and will not go away, occurs with or without vomiting, or is felt going from your stomach area through to your back. These may be symptoms of pancreatitis.

Before using Victoza®, tell your doctor about all the medicines you take, especially sulfonylurea medicines or insulin, as taking them with Victoza® may affect how each medicine works. If you use Victoza® with insulin, you may give both injections in the same body area (for example, your stomach area), but not right next to each other.

Also tell your doctor if you have severe stomach problems such as slowed emptying of your stomach (gastroparesis) or problems with digesting food; have or have had kidney or liver problems; have any other medical conditions; or are pregnant or plan to become pregnant. Tell your doctor if you are breastfeeding or plan to breastfeed. It is unknown if Victoza® will harm your unborn baby or if Victoza® passes into your breast milk.

Your risk for getting hypoglycemia, or low blood sugar, is higher if you take Victoza® with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. The dose of your sulfonylurea medicine or insulin may need to be lowered while taking Victoza®.

Victoza® may cause nausea, vomiting, or diarrhea leading to dehydration, which may cause kidney failure. This can happen in people who have never had kidney problems before. Drinking plenty of fluids may reduce your chance of dehydration.

The most common side effects with Victoza® include headache, nausea, and diarrhea. Nausea is most common when first starting Victoza®, but decreases over time in most people. Immune system related reactions, including hives, were more common in people treated with Victoza® compared to people treated with other diabetes drugs in medical studies.

Please click here for Victoza® Prescribing Information, including Medication Guide.

Talk to your doctor about the importance of diet and exercise in your treatment plan.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Novo Nordisk provides patient assistance for those who qualify.
Please call 1-866-310-7549 to learn more about Novo Nordisk assistance programs.



LEVEMIR®Back to Top

Indications and Usage:


What is Levemir® (insulin detemir [rDNA origin] injection)?

  • Levemir® (insulin detemir [rDNA origin] injection) is a man-made long-acting insulin used to control high blood sugar in adults and children with diabetes mellitus.
  • It is not recommended to use Levemir® to treat diabetic ketoacidosis.

Important Safety Information:


Who should not use Levemir®?

  • Do not use Levemir® if you are allergic to any of its ingredients.

What should I tell my healthcare provider before taking Levemir®?
  • About all of your medical conditions, including liver or kidney problems
  • If you are pregnant, breastfeeding, or plan to do either
  • About all prescription and nonprescription medicines you take, including supplements, as your dose may need to change.

How should I take Levemir®?
  • Inject Levemir® under the skin of your stomach area, upper arms, or thighs, but never into a vein or muscle.
  • Do not dilute or mix Levemir® with any other insulin or injectable diabetes medicine or use in an insulin pump. Give yourself separate injections in the same body area, but not next to each other.
  • Do not change your dose or type of insulin unless you are told to by your healthcare provider.
  • Do not share needles, insulin pens, or syringes.
  • Check your blood sugar levels as directed by your healthcare provider.

What should I consider while using Levemir®?
  • Alcohol, including beer and wine, may affect your blood sugar.
  • Be careful when driving a car or operating machinery. You may have difficulty concentrating or reacting if you have low blood sugar. Talk to your healthcare provider if you often have low blood sugar or no warning signs of low blood sugar.

What are the possible side effects of Levemir®?
  • Low blood sugar (hypoglycemia), including when too much is taken. Some symptoms include sweating, shakiness, confusion, and headache. Severe low blood sugar can cause unconsciousness, seizures, and death.
  • Serious allergic reactions may occur. Get medical help right away, if you develop a rash over your whole body, have trouble breathing, a fast heartbeat, or sweating.
  • Other side effects include injection site reactions (like redness, swelling, and itching), skin thickening or pits at the injection site, and weight gain.

Please click here for Levemir® Prescribing Information.

Levemir® is a prescription medicine.

Talk to your doctor about the importance of diet and exercise in your treatment plan.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Novo Nordisk provides patient assistance for those who qualify.
Please call 1-866-310-7549 to learn more about Novo Nordisk assistance programs.



NOVOLOG®Back to Top

Indications and Usage:


What is NovoLog® (insulin aspart [rDNA origin] injection)?

  • NovoLog® (insulin aspart [rDNA origin] injection) is a man-made insulin used to control high blood sugar in adults and children with diabetes mellitus.

Important Safety Information:


Who should not use NovoLog®?

  • Do not use NovoLog® if your blood sugar is too low (hypoglycemia) or you are allergic to any of its ingredients.

What should I tell my healthcare provider before taking NovoLog®?
  • About all of your medical conditions, including liver or kidney problems.
  • If you are pregnant, breastfeeding, or plan to do either.
  • About all prescription and nonprescription medicines you take, including supplements, as your dose may need to change.

How should I take NovoLog®?
  • Eat a meal within 5 to 10 minutes after using NovoLog®, a fast-acting insulin, to avoid low blood sugar. Do not inject NovoLog® if you do not plan to eat right after your injection or bolus pump infusion.
  • Do not mix NovoLog® with any other insulin when used in a pump or with any insulin other than NPH when used with injections by syringe.
  • Do not change your dose or type of insulin unless you are told to by your healthcare provider.
  • Do not share needles, insulin pens, or syringes.
  • Check your blood sugar levels as directed by your healthcare provider.

What should I consider while using NovoLog®?
  • Alcohol, including beer and wine, may affect your blood sugar.
  • Be careful when driving a car or operating machinery. You may have difficulty concentrating or reacting if you have low blood sugar. Talk to your healthcare provider if you often have low blood sugar or no warning signs of low blood sugar.

What are the possible side effects of NovoLog®?
  • Low blood sugar, including when too much is taken. Some symptoms include sweating, shakiness, confusion, and headache. Severe low blood sugar can cause unconsciousness, seizures, and death.
  • Serious allergic reactions may occur. Get medical help right away, if you develop a rash over your whole body, have trouble breathing, a fast heartbeat, or sweating.
  • Other side effects include injection site reactions (like redness, swelling, and itching), skin thickening or pits at the injection site, swelling of your hands and feet, vision changes, low potassium in your blood, and weight gain.
Please click here NovoLog® Prescribing Information.

NovoLog® is a prescription medication.

Talk to your doctor about the importance of diet and exercise in your treatment plan.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Novo Nordisk provides patient assistance for those who qualify.
Please call 1-866-310-7549 to learn more about Novo Nordisk assistance programs.



NOVOLOG® MIX 70/30®Back to Top

Indications and Usage:


What is NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin])?

  • NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) is a man-made insulin used to control high blood sugar in adults with diabetes mellitus.
  • It is not known if NovoLog® Mix 70/30 is safe or effective in children.

Important Safety Information:

Who should not use NovoLog® Mix 70/30?

  • Do not use NovoLog® Mix 70/30 if your blood sugar is too low (hypoglycemia) or you are allergic to any of its ingredients.

What should I tell my healthcare provider before taking NovoLog® Mix 70/30?
  • About all of your medical conditions, including liver or kidney problems.
  • If you are pregnant, breastfeeding, or plan to do either.
  • About all prescription and nonprescription medicines you take, including supplements, as your dose may need to change.
How should I take NovoLog® Mix 70/30?
  • NovoLog® Mix 70/30 starts acting fast. If you have type 1 diabetes, inject within 15 minutes before you eat a meal. If you have type 2 diabetes, inject within 15 minutes before or after starting your meal.
  • Inject NovoLog® Mix 70/30 under the skin of your stomach area, upper arms, buttocks, or thighs, but never into a vein or muscle.
  • Do not mix NovoLog® Mix 70/30 with other insulin products or use in an insulin pump.
  • Do not change your dose or type of insulin unless you are told to by your healthcare provider.
  • Do not share needles, insulin pens, or syringes.
  • Check your blood sugar levels as directed by your healthcare provider.

What should I consider while using NovoLog® Mix 70/30?
  • Alcohol, including beer and wine, may affect your blood sugar.
  • Be careful when driving a car or operating machinery. You may have difficulty concentrating or reacting if you have low blood sugar. Talk to your healthcare provider if you often have low blood sugar or no warning signs of low blood sugar.

What are the possible side effects of NovoLog® Mix 70/30?
  • Low blood sugar, including when too much is taken. Some symptoms include sweating, shakiness, confusion, and headache. Severe low blood sugar can cause unconsciousness, seizures, and death.
  • Serious allergic reactions may occur. Get medical help right away, if you develop a rash over your whole body, have trouble breathing, a fast heartbeat, or sweating.
  • Other side effects include low potassium in your blood, injection site reactions (like redness, swelling, and itching), skin thickening or pits at the injection site, weight gain, swelling of your hands and feet, and vision changes.
Please click here for NovoLog® Mix 70/30 Prescribing Information.

NovoLog® Mix 70/30 is a prescription medication.

Talk to your doctor about the importance of diet and exercise in your treatment plan.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Novo Nordisk provides patient assistance for those who qualify.
Please call 1-866-310-7549 to learn more about Novo Nordisk assistance programs.



GLUCAGEN®Back to Top

Indications and Usage:

GlucaGen® (glucagon [rDNA origin] for injection) is a prescription medicine used to treat very low blood sugar (severe hypoglycemia) that can happen in people who have diabetes and use insulin. Symptoms of severe hypoglycemia include confusion, loss of consciousness, and seizures. You should only give GlucaGen® injection if (1) the person is unconscious or (2) the person is having a seizure or (3) the person is confused and unable to eat sugar or a sugar-sweetened product. Less severe cases of hypoglycemia should be treated right away by eating sugar or a sugar sweetened product such as a regular soft drink or fruit juice. GlucaGen® does not work if it is taken by mouth.

Important Safety Information:

Do not use GlucaGen® if you are allergic to glucagon or lactose, have a tumor of the adrenal gland called a pheochromocytoma, or have a tumor of the pancreas called insulinoma. Hypoglycemia may happen again after receiving GlucaGen® treatment. You must be given a fast-acting source of sugar followed by a long-acting source of sugar by mouth as soon as you are awake and able to swallow.

Tell your doctor about all medicines you take and all of your medical conditions, including if you are pregnant or breastfeeding. GlucaGen® may affect the way other medicines work, and other medicines may affect how GlucaGen® works.

GlucaGen® may cause serious side effects including allergic reactions. Symptoms of a severe allergic reaction may include rash or itching, raised red patches on your skin (hives), swelling of the face, lips, tongue or throat, problems breathing or swallowing, very high or very low blood pressure, or fast or slow heart beat. The most common side effects of GlucaGen® include nausea and vomiting.

Please click here for GlucaGen® Hypokit Prescribing Information.

GlucaGen® is a prescription medication.

Talk to your doctor about the importance of diet and exercise in your treatment plan.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Novo Nordisk provides patient assistance for those who qualify. Please call 1-866-310-7549 to learn more about Novo Nordisk assistance programs.



NOVOSEVEN® RT Back to Top

Indications and Usage:

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; treatment of bleeding episodes in patients with congenital Factor VII deficiency and prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency.

Important Safety Information:

Serious thrombotic side effects are associated with the use of NovoSeven® RT outside of the uses approved by the FDA. These thrombotic side effects are blood clots that form in arteries and veins and can cause harm and may lead to death. Your doctor should discuss the risks and explain the signs and symptoms of thrombotic side effects to you. Your doctor should monitor you for blood clots during treatment with NovoSeven® RT.

Thrombotic side effects following the use of NovoSeven® RT occurred in 0.3% of all bleeds that were treated for FDA-approved uses. The rate of 0.2% was observed in hemophilia patients with inhibitors, and the rate was higher in patients with acquired hemophilia (4%). Thrombotic events (fatal and non-fatal) have been reported following use of NovoSeven® RT for all FDA-approved uses.

Some patients have conditions that may increase the risk of thrombotic side effects. These include clogged arteries, blood clots that form throughout the body instead of at the place of injury (called disseminated intravascular coagulation), a type of blood poisoning called septicemia, and crush injury, which is when a body part is crushed or squeezed between heavy or immobile objects. Also, people taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) at the same time that they are taking NovoSeven® RT may be at increased risk for thrombotic side effects. NovoSeven® RT should be used with caution in patients who have an increased risk for thrombotic side effects. These include, but are not limited to, patients with a history of heart disease, liver disease, patients who have limited movement following surgery, elderly patients, and neonates (babies who are 4 weeks old or younger). In each of these situations, the potential benefit of treatment with NovoSeven® RT should be weighed against the risk of these complications.

Some patients with Factor VII deficiency have developed resistance (antibodies) to Factor VII after treatment with NovoSeven® RT. Factor VII-deficient patients should be monitored for antibody formation before and after administration of NovoSeven® RT.

People who have ever had a bad reaction to NovoSeven® RT or to proteins from mice, hamsters, or “bovines” (such as an ox or cow) should consult their physician prior to using NovoSeven® RT.

The most common side effects in patients treated with NovoSeven® RT are rash, itching, hives, fever, lowered response to treatment, and blood clots in veins.

Please click here for NovoSeven® RT Prescribing Information.

NovoSeven® RT is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Novo Nordisk provides patient assistance for those who qualify. Please call 1-866-310-7549 to learn more about Novo Nordisk assistance programs.




NORDITROPIN® Back to Top

Indications and Usage:

Norditropin® (somatropin [rDNA origin] injection) is used to treat: children who have growth failure because of low or no growth hormone; children who are short (in stature) and who have Noonan syndrome or Turner syndrome; children who are short (in stature) because they were born small (small for gestational age-SGA) and have not caught-up in growth by age 2 to 4 years; and adults who do not make enough growth hormone.

Important Safety Information:

Do not use Norditropin® if: you have a critical illness caused by certain types of heart or stomach surgery, trauma or breathing (respiratory) problems; you are a child with Prader-Willi syndrome who is severely obese or has breathing problems including sleep apnea; you have cancer or other tumors; your healthcare provider tells you that you have certain types of eye problems caused by diabetes; you are a child with closed bone growth plates (epiphyses) or you are allergic to any of the ingredients in the medicine.

Before you take Norditropin®, tell your healthcare provider if you: have diabetes; had cancer or any tumor; have any other medical condition; are pregnant or plan to become pregnant; are breast-feeding or plan to breast-feed.

Norditropin® can cause serious side effects, including: high risk of death in people who have critical illnesses because of heart or stomach surgery, trauma or serious breathing (respiratory) problems; high risk of death in children with Prader-Willi syndrome who are severely obese or have breathing problems including sleep apnea; return of tumor or cancerous growths; high blood sugar (hyperglycemia); increase in pressure in the skull (intracranial hypertension); swollen hands and feet due to fluid retention; decrease in thyroid hormone levels; hip and knee pain or a limp in children (slipped capital femoral epiphysis); worsening of pre-existing curvature of the spine (scoliosis); middle ear infection, hearing problems or ear problems in patients with Turner syndrome.

Patients with Noonan syndrome and Turner syndrome should be closely monitored by their doctors as they are more likely to have congenital heart disease.

The most common side effects of Norditropin® include: headaches, muscle pain, joint stiffness, high blood sugar (hyperglycemia), sugar in your urine (glucosuria), swollen hands and feet due to fluid retention, and redness and itching in the area you inject.

If you have headaches, eye problems, nausea or vomiting (these may be symptoms of raised pressure in the brain), contact your healthcare provider right away.

Norditropin® may affect how other medicines work, and other medicines may affect how Norditropin® works so be sure to tell your healthcare provider about all the medicines you take including prescription and non-prescription medicines, vitamins, and herbal supplements.

herbal supplements. Especially tell your healthcare provider if you take: glucocorticoid medication, thyroid hormone, insulin or other medicine for diabetes, medicines that are metabolized by the liver (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporine), or oral estrogen replacement medicine.

Please click here for Norditropin® Prescribing Information.

Norditropin® is a prescription medication. Talk to your doctor to see if Norditropin® is right for you or your child.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Novo Nordisk provides patient assistance for those who qualify. Please call 1-866-310-7549 to learn more about Novo Nordisk assistance programs.